Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian
GET TICKETS

Analyst: Don't Expect Anika's Latest FDA Cleared Treatment To Impact 2018

Share:
Analyst: Don't Expect Anika's Latest FDA Cleared Treatment To Impact 2018

Anika Therapeutics Inc (NASDAQ: ANIK) announced Wednesday it has received clearance from the U.S. Food and Drug Administration for its HA-based bone void filler, which is used to fill bone voids or defects of the skeletal system.

The Analyst

Barrington Research's Michael Petusky maintains an Outperform rating on Anika's stock with an unchanged $57 price target.

The Thesis

Anika's bone filler offers an invasive alternative versus the current standard of health that involves surgery, Petusky said in a note. As such, the company or a distribution partner will look to highlight this compelling feature as an advantage as it looks to position the product in the marketplace. The cost benefits of the bone repair treatment as opposed to bone grafting surgeries is significant and surgical procedures by default come with an increased risk of complication.

Anika believes the market size it can address is around $300 million, Petusky said. For the time being, the FDA's approval won't have any material revenue impact in 2018 and a 2019-2020 time frame is the earliest the new product could show any notable revenue impact. Nevertheless, the latest development represents "another positive step" in the company's goal of building out a meaningful regenerative medicine franchise.

Price Action

Shares of Anika were trading higher by around 0.2 percent late Thursday morning.

Related Links:

Markets Headed Higher In Early Going; Jobless Claims Remain Unchanged

Markets Mostly Higher; Live Ventures Shares Climb After Reporting 92% Rise in FY17 Revenue

Latest Ratings for ANIK

DateFirmActionFromTo
Feb 2019DowngradesBuyNeutral
Jul 2018UpgradesMarket PerformOutperform
Jun 2018DowngradesOverweightEqual-Weight

View More Analyst Ratings for ANIK
View the Latest Analyst Ratings

Posted-In: Barrington Research Bone Void Filler Michael Petusky SurgeryAnalyst Color News FDA Analyst Ratings Best of Benzinga

 

Related Articles (ANIK)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ORCLMaintains59.0
ORCLMaintains61.0
FDXMaintains200.0
ORCLMaintains59.0
ACNMaintains186.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Why This Investor Sees Gain Capital As A Possible Winner From Bitcoin

8 Retail Stocks That Outperformed The Record-Breaking Holiday Shopping Season